INTRODUCTION
============

Colorectal cancer (CRC) is a leading common cancer in China and in the world ([@B1]). In many countries, the incidence of CRC shows no sign of declining and this contributes to an increasing burden of cancer-related morbidity and mortality. Although it has been well-established that exposure to environmental carcinogens is the major risk factor in the etiology of CRC, not all individuals exposed to these carcinogens develop the cancer. This indicates that CRC is multifactorial in nature, and the risk of developing CRC is influenced not only by environmental factors, but also by an underlying genetic predisposition ([@B2]).

Among the important factors affecting CRC predisposition, low penetrance genetic polymorphisms have received increasing attention in the last decade ([@B3], [@B4], [@B5]). Such polymorphisms could influence the function of the protein products encoded, and if these polymorphisms occur to the genes implicated in carcinogenesis, the interindividual variation in the functioning of the protein products could mediate the susceptibility of different individuals to the development of cancer. Considering the fact that environmental carcinogens constitute the most important risk factors for CRC, genetic polymorphisms of genes in the xenobiotic-metabolizing pathways have been widely investigated for their role in influencing CRC risk ([@B6], [@B7], [@B8]).

Glutathione S-transferases (GSTs) represent a superfamily of phase II cellular detoxification enzymes, which are involved in the metabolism of xenobiotics. Specifically, GSTs catalyze the conjugation between glutathione and electrophilic xenobiotics, thereby eliminating the harmful mutagenic or carcinogenic compounds present in diet and tobacco smoke. Several classes of GSTs have been identified, with *GSTT1*, M1 and P1 being the most well-characterized forms ([@B9], [@B10]). Polymorphisms within the genes encoding for the three GSTs, specifically *GSTT1* and *GSTM1* null polymorphisms as well as *GSTP1* Ile105Val polymorphism, have been reported to cause reduction or total elimination of their enzymatic function ([@B9], [@B11]). With these in mind, we hypothesized that the mentioned *GSTT1*, *GSTM1*, and *GSTP1* polymorphisms could influence the risk of CRC. Limited data is currently available on the polymorphic frequency of these genes in the Chinese population and hence, the associated CRC risk in the population. Therefore, the present study was undertaken to investigate the frequencies of *GSTT1*, *GSTM1*, and *GSTP1* polymorphic genotypes among Chinese and their association with the risk of CRC.

MATERIALS AND METHODS
=====================

Study subjects
--------------

A total of 264 cases (137 males, 127 females) and 317 controls (165 males, 152 females) were recruited into the study. The subjects were recruited between July 2012 and December 2013 from Shandong Cancer Hospital and Institute. Cases were histopathologically confirmed CRC patients, whereas controls were healthy individuals randomly selected from a cancer screening program. Controls were age- and sex-matched to the cases in terms of frequency. The demographic characteristics of the subjects are shown in [Table 1](#T1){ref-type="table"}.

Genotyping
----------

Genomic DNA was extracted from the blood samples obtained using EasyPure Blood Genomic DNA Kit (TransGen Biotech, Beijing, China). The *GSTT1* and *GSTM1* null polymorphisms were genotyped by using multiplex polymerase chain reaction (PCR) technique with the beta-globin gene served as the internal control. The primers used for *GSTT1* genotyping were 5\'-TTCCTTACTGGTCCTCACATCTC-3\' and 5\'-TCACCGGATCATGGCCAGCA-3\', which produced a fragment of 459 bp. On the other hand, the primers used for *GSTM1* genotyping were 5\'-GAACTCCCTGAAAAGCTAAAGC-3\' and 5\'-GTTGGGCTCAAATATACGGTGG-3\', which produced a fragment of 219 bp. The 268 bp beta-globin gene was amplified by using 5\'-CAACTTCATCCACGTTCACC-3\' and 5\'-GAAGAGCCAAGGACAGTTAC-3\' primers. The multiplex PCR was performed under the following conditions: 5 min of initial denaturation at 94℃, followed by 35 cycles of 1 min at 94℃, 30 sec at 56℃, 45 sec at 72℃, and a final extension for 5 min at 72℃. The PCR products were separated on 3% agarose gels for visualization of the bands for inferring of the genotypes ([Fig. 1](#F1){ref-type="fig"}).

On the other hand, the *GSTP1* polymorphism was genotyped using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. The PCR primers used were 5\'-GTAGTTTGCCCAAGGTCAAG-3\' and 5\'-AGCCACCTGAGGGGTAAG-3\'. The PCR condition was 5 min of initial denaturation at 94℃, followed by 35 cycles of 1 min at 94℃, 30 sec at 58℃, 30 sec at 72℃, and a final extension for 5 min at 72℃. The amplification gave a product of 433 bp in size. The PCR products were then digested by using BsmAI restriction enzyme. This generated a 329 bp and a 104 bp fragment for the homozygous wild type (Ile/Ile) genotype, and a 222 bp, a 107 bp, and a 104 bp fragment for the homozygous variant (Val/Val), with the last two fragments appeared as a single band due to the small size difference ([Fig. 1](#F1){ref-type="fig"}). Heterozygous variant genotype (Ile/Val) was detected by the presence of all the above bands in agarose gel. For all polymorphisms, approximately 10% of the samples were chosen at random and sequenced to confirm the genotypes.

Statistical analysis
--------------------

Difference in genotype distribution between cases and controls was calculated by using a chi-square test. The odds ratios (ORs) and 95% confidence intervals (CI) were calculated by using unconditional logistic regression analysis to evaluate the association between the polymorphisms and CRC risk. *P* values of less than 0.05 were considered statistically significant.

Ethics statement
----------------

The study was conducted according to the Declaration of Helsinki. The study protocol was reviewed and approved by the institutional review board of Shandong Academy of Medical Sciences (Ref: SAMS/SCHI/2012/28020339, English Version). Blood samples were collected from the subjects after obtaining written informed consent.

RESULTS
=======

Prevalence of *GSTT1*, *GSTM1*, and *GSTP1* polymorphisms
---------------------------------------------------------

The prevalence of *GSTT1*, *GSTM1*, and *GSTP1* polymorphisms is shown in [Table 2](#T2){ref-type="table"}. For *GSTT1* and *GSTM1* polymorphisms, genotype was defined as \'non-null\' if at least one copy of the gene was present. Of the 264 cases, 125 (47.3%) carried non-null *GSTT1* genotype and 139 (52.7%) showed null genotype. On the other hand, of the 317 controls, 190 (59.9%) and 127 (40.1%) carried non-null and null GSTT1 genotypes respectively. A significant difference was observed between cases and controls in terms of genotypic distribution (*P*=0.003). A significant genotypic distribution difference was also seen among cases and controls for *GSTM1* polymorphism (*P*=0.007). A total of 122 (46.2%) of the cases and 182 (57.4%) of the controls were non-null for *GSTM1*. In contrast, 142 (53.8%) of the cases and 135 (42.6%) of the controls had null genotype for the polymorphism. Hardy-Weinberg test was not performed for the two polymorphisms due to the inability to distinguish between homozygous wild type and heterozygous *GSTT1* and *GSTM1* individuals in the analysis.

For the *GSTP1* polymorphism, 141 (53.4%), 101 (38.3%) and 22 (8.3%) of the cases carried homozygous wild type (Ile/Ile), heterozygous (Ile/Val) and homozygous variant (Val/Val) genotypes respectively. A total of 177 (55.8%) of the controls were homozygous wild type for the polymorphism, while 121 (38.2%) were heterozygous, and 19 (5.9%) were homozygous variant. No significant difference in genotypic distribution was observed between cases and controls (*P*=0.559 for homozygous wild type, *P*=0.983 for heterozygous and *P*=0.275 for homozygous variant). The genotypic distribution did not deviate significantly from the Hardy-Weinberg equilibrium (*P*=0.52 for cases, *P*=0.78 for controls).

Association of *GSTT1*, *GSTM1*, and *GSTP1* polymorphisms with CRC risk
------------------------------------------------------------------------

For *GSTT1* and *GSTM1* polymorphisms, the non-null genotype served as the reference for risk association analysis and was given an odds ratio (OR) value of 1. For *GSTT1* polymorphisms, a significantly increased CRC risk association was observed for the null genotype (OR, 1.66; 95% CI, 1.20-2.31; *P*=0.003) ([Table 3](#T3){ref-type="table"}). Similarly, the *GSTM1* null genotype also resulted in a significantly higher CRC risk association in the population studied (OR, 1.57; 95% CI, 1.13-2.18; *P*=0.007) ([Table 3](#T3){ref-type="table"}).

On the other hand, for *GSTP1* polymorphism, the homozygous wild type (Ile/Ile) genotype served as the reference. The heterozygous Ile/Val genotype showed a slightly increased risk of CRC (OR, 1.05; 95% CI, 0.74-1.48) ([Table 3](#T3){ref-type="table"}). However, the risk was not statistically significant (*P*=0.790). Similarly, a non-statistically significant increased CRC risk association was observed for *GSTP1* homozygous variant genotype (OR, 1.45; 95% CI, 0.76-2.80, *P*=0.261).

Combination analysis of *GSTT1* and *GSTM1* polymorphisms and its association with CRC risk
-------------------------------------------------------------------------------------------

Since *GSTT1* and *GSTM1* polymorphisms resulted in a significantly higher CRC risk, we investigated the combined effect of the two polymorphisms in influencing the risk of CRC. In the combination analysis, individuals who simultaneously carried the non-null genotypes for both polymorphisms served as the reference. The various *GSTT1* and *GSTM1* combinations and their associations with CRC risk is shown in [Table 4](#T4){ref-type="table"}. The *GSTT1* non-null and *GSTM1* null combination resulted in a significantly decreased CRC risk (OR, 0.55; 95% CI, 0.32-0.97; *P*=0.038). Similarly, a decreased CRC risk was observed for the combination of *GSTT1* null and *GSTM1* non-null genotypes, although the association was not significant (OR, 0.71; 95% CI, 0.40-1.25; *P*=0.238). On the other hand, the *GSTT1* null and *GSTM1* null genotypes, which resulted in a significantly increased risk when analyzed separately, showed a stronger risk association when analyzed in combination (OR, 1.95; 95% CI, 1.33-2.85; *P*\<0.001) ([Table 4](#T4){ref-type="table"}).

DISCUSSION
==========

GSTs constitute a class of detoxification enzymes which play a pivotal role in the metabolism of carcinogens, environmental pollutants, and chemotherapeutic drugs. The enzymes have received much attention in CRC studies due to their ability to neutralize several carcinogens known to associate with the cancer, such as heterocyclic aromatic amines (HAAs) and polycyclic aromatic hydrocarbons (PAHs) ([@B12]). Several functional polymorphisms within the genes encoding for *GSTT1*, M1 and P1 have been described. The *GSTT1* and *GSTM1* null polymorphisms could lead to the total elimination of the activity of GSTT1 and M1 enzymes respectively, due to homozygosity for deletion of these genes ([@B13]). On the other hand, the *GSTP1* Ile105Val substitution polymorphism could result in a decreased enzymatic activity of the protein product ([@B14]). The impaired functioning of these enzymes could present an increased risk of CRC to the individuals carrying the variant genotypes, and data on the distribution of these polymorphisms are important for the risk estimation.

The frequencies of these polymorphisms, and therefore the associated risk values, have been shown to differ from ethnicity to ethnicity and from population to population. Limited data is currently available regarding the prevalence of these polymorphisms in CRC patients and cancer-free controls in China. More often than not, studies investigating the prevalence of these polymorphisms in the above population are of small sample sizes, and did not incorporate the polymorphisms of all the three genes simultaneously ([@B15], [@B16]). Since GSTT1, M1, and P1 enzymes share common substrates, studies which do not include all the three genes in their analyses may result in misleading interpretations, as deficiency in one form of GST may be compensated by the presence of the other forms of GST. The present study was therefore undertaken to address the scarcity of these data.

It has been previously reported that the prevalence of *GSTT1* null genotype ranged from 16%-64% in Asian populations ([@B13]). Our results were in agreement with this observation. The distribution of *GSTT1* polymorphic genotypes among CRC patients in our study was highly similar to that reported by Yang et al. ([@B6]), who investigated the frequency of the polymorphism in the same population. The prevalence of non-null and null *GSTT1* genotypes in our study were 47.3% and 52.7% respectively, whereas those reported by Yang et al. ([@B6]) were 49.1% and 50.9% respectively. These results were, however, not in agreement with the frequencies reported by Koh et al. ([@B7]) in a Singaporean Chinese population, which showed that the non-null genotype was more prevalent than null genotype in the population (61.3% vs. 38.8%). The genotype distribution among controls in our study was also in agreement with Yang et al. ([@B6]), in that the prevalence of non-null genotype was higher. However, the prevalence of non-null and null genotypes reported by Yang et al. ([@B6]) were 51.1% and 48.9% respectively, while ours were 59.9% and 40.1%, which were closer to the frequency reported by Koh et al. ([@B7]), i.e. 59.2% non-null genotype and 40.8% null genotype. We observed a statistically significant difference in the genotypic distribution between cases and controls in our study, while Yang et al. ([@B6]) and Koh et al. ([@B7]) reported no significant difference in the genotypic distribution. We further found a risk association between the null genotype of the polymorphism with CRC risk, an observation which was not seen in the two mentioned research groups, but was in concordance with Wang et al. ([@B17]) in India, another Asian population.

For *GSTM1* polymorphism, the null genotype appeared to be more prevalent than the non-null genotype among cases in our study (53.8% vs. 46.2%), which was in agreement with Yang et al. ([@B6]) but in disagreement with Koh et al. ([@B7]). However, the frequencies reported in all research groups corresponded to previous estimation of the frequency of *GSTM1* null genotype among Asians, which was in the range of 33%-63% ([@B13]). Yang et al. ([@B6]) reported a frequency of 41.3% non-null genotype and 58.7% null genotype among CRC patients. On the other hand, Koh et al. ([@B7]) reported a frequency of 51.3% non-null genotype and 48.8% null genotype among the same patients. However, among the controls, our results agreed with Koh et al. ([@B7]) and disagreed with Yang et al. ([@B6]). We reported a higher frequency of non-null genotype than null genotype among controls (57.4% vs. 42.6%), while the frequencies were 54.9% vs. 45.1% for Koh et al. ([@B7]) and 41.7% vs. 58.4% for Yang et al. ([@B6]). Similar to *GSTT1* polymorphism, we found a statistically significant difference in the distribution *GSTM1* polymorphic genotypes between cases and controls in our study, while the other two groups reported no statistically significant difference ([@B6], [@B7]). We also found a significant risk association between *GSTM1* null genotype and CRC risk, which also agreed to the findings reported by Wang et al. ([@B17]). Further, we showed that the combination of *GSTT1* null and *GSTM1* null genotypes could present greater CRC risk to their carriers.

No data are available on the prevalence of *GSTP1* polymorphism in China, although there were such data for Chinese ethnicity in Singapore and Taiwan ([@B7], [@B8]). In our study, no statistically significant difference exists regarding the distribution of *GSTP1* polymorphic genotypes among CRC patients and controls. This observation agrees to those reported in Singapore and Taiwan, which also showed a lack of association between *GSTP1* polymorphism and CRC risk ([@B7], [@B8]). However, our observation was in contrast to those reported by Vlaykova et al. ([@B18]) in a Bulgarian population and Hezova et al. ([@B19]) in the Central European population, which showed that the *GSTP1* Ile/Val heterozygous genotype could reduce CRC risk. This difference clearly indicates the importance of ethinicity in influencing CRC risk modulation by genetic polymorphisms.

In conclusion, although small sample size constituted a limitation for our study, our results suggested that *GSTT1* and *GSTM1* polymorphisms could increase the risk of CRC among the Chinese population. Further, a combination of *GSTT1* and *GSTM1* null genotypes could present a greater CRC risk for their carriers. We also demonstrated a lack of association between *GSTP1* polymorphism and CRC risk among Chinese.

We thank all the subjects who took part in this study.
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![Representative genotyping result. Lane 1: DNA marker. Lane 2: *GSTT1* non-null, *GSTM1* non-null (459 bp, 268 bp, 219 bp). Lane 3: *GSTT1* non-null, *GSTM1* null (459 bp, 268 bp). Lane 4: *GSTT1* null, *GSTM1* non-null (268 bp, 219 bp). Lane 5: *GSTT1* null, *GSTM1* null (268 bp). Lane 6: *GSTP1* Ile/Ile (329 bp, 104 bp). Lane 7: *GSTP1* Val/Val (222 bp, 107 bp, 104 bp). Lane 8: *GSTP1* Ile/Val (329 bp, 222 bp, 107 bp, 104 bp).](jkms-29-1488-g001){#F1}
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